USFDA still struggling to conduct pending drug inspections after Covid

Q: How long will it take to read this news story?

The story "USFDA still struggling to conduct pending drug inspections after Covid" has 1187 words across 50 sentences, which will take approximately 5 - 10 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "USFDA still struggling to conduct pending drug inspections after Covid" was covered 8 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 384 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22376629</li><li>URL: https://beamstart.com/news/usfda-still-struggling-to-conduct-17255471314314</li></ul>

Business Standard Logo Business Standard 8h ago

USFDA still struggling to conduct pending drug inspections after Covid - Business Standard

Quick Summary:

Federal regulators responsible for the safety of the US drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the US and across the world, The Associated Press has found.

The firms that are overdue for safety and quality inspections represent about 42 per cent of the 4,700 plants that are currently registered to produce drugs for the US and previously underwent FDA review before May 2019, the AP found.

An AP analysis of Food and Drug Administration data shows that agency staffers have not returned to roughly 2,000 pharmaceutical manufacturing firms to conduct surveillance inspections since before the pandemic.